Loading...
Loading...
ZLAB| Name | Value |
|---|---|
| Revenues | 87.1M |
| Cost of Revenue | 33.6M |
| Gross Profit | 53.5M |
| Operating Expense | 123.8M |
| Operating I/L | -70.3M |
| Other Income/Expense | 16.8M |
| Interest Income | 9.7M |
| Pretax | -53.5M |
| Income Tax Expense | 9.5M |
| Net Income/Loss | -53.5M |
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include a range of treatments such as Zejula, Optune, NUZYRA, and Qinlock, targeting various medical conditions. Additionally, Zai Lab is actively developing a pipeline of novel therapies for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases, to generate revenue and expand its market presence.
